Original: https://doi.org/10.1080/14756366.2025.2606434
Monoamine oxidase B (MAO-B) inhibitors are commonly used to treat Parkinson’s disease, because they help increase dopamine levels in the brain.
In this study, researchers designed and made a new group of chemical compounds and tested them to see how well they block the human MAO-B enzyme.
Main findings
- Most of the new compounds were able to inhibit MAO-B.
- Two compounds, 29 and 34, showed the strongest effects.
- Their inhibitory strength (IC50 values) was extremely low (about 0.07 micromolar), meaning they are very powerful.
- They were also highly selective for MAO-B over other similar enzymes (high selectivity index).
- Both compounds performed better than rasagiline, a currently used MAO-B inhibitor for Parkinson’s disease.
How they work
Further testing showed that these compounds:
- Act as mixed reversible inhibitors, meaning they can bind to the enzyme in more than one way, and their effect is not permanent.
- Computer modeling (molecular docking) showed that compound 29 fits very well and binds stably in the MAO-B active site.
Safety and cell studies
- The compounds showed low toxicity to nerve cells.
- They also protected nerve cells from damage caused by 6-OHDA, a chemical commonly used to mimic Parkinson’s-related cell damage in laboratory studies.
Conclusion
These results suggest that compounds 29 and 34 are promising new candidates for Parkinson’s disease treatment and deserve further development and testing.